Clinical Trials Browser

Phase 1/2 × Melanoma × Solutions × Clear all

NCT04752826 2026-02-18

MK-3475-D20

Phase 1/2 Recruiting

DermatologicGynecologicLymphoid

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Phase 1/2 Active not recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis